Investigational Drug Details
| Drug ID: | D120 |
| Drug Name: | Elobixibat |
| Synonyms: | Elobixibat |
| Type: | Chemical drug |
| DrugBank ID: | DB12486 |
| DrugBank Description: | Elobixibat has been used in trials studying the treatment and basic science of Dyslipidemia, Constipation, Chronic Constipation, Functional Constipation, and Chronic Idiopathic Constipation. |
| PubChem ID: | 9939892 |
| CasNo: | 439087-18-0 |
| Repositioning for NAFLD: | No |
| SMILES: | O=S1(=O)c2c(N(CC(C1)(CCCC)CCCC)c1ccccc1)cc(c(c2)OCC(=O)N[C@@H](C(=O)NCC(=O)O)c1ccccc1)SC |
| Structure: |
|
| InChiKey: | XFLQIRAKKLNXRQ-UUWRZZSWSA-N |
| Molecular Weight: | 695.904 |
| DrugBank Targets: | -- |
| DrugBank MoA: | -- |
| DrugBank Pharmacology: | -- |
| DrugBank Indication: | -- |
| Targets: | SLC10A1 inhibitor |
| Therapeutic Category: | Gastrointestinal drug |
| Clinical Trial Progress: | Phase 2 completed (NCT04235205: Elobixibat resolved constipation in the short-term, and was well tolerated with both short-term and long-term treatment. The evidence supports the use of this novel approach to increase intracolonic concentrations of endogenous bile acid for the treatment of chronic constipation.) |
| Latest Progress: | Under clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0034 | NCT04235205 | Phase 2 | Completed | No Results Available | January 29, 2020 | November 16, 2021 | Details |
| L0144 | NCT04006145 | Phase 2 | Completed | Has Results | June 6, 2019 | September 27, 2021 | Details |
| L0407 | JPRN-jRCTs031200144 | Phase 2 | Recruiting | No Results Available | 12/10/2020 | 18 October 2021 | Details |
| L0440 | JPRN-JapicCTI-205120 | Phase 2 | Not Recruiting | No Results Available | 21/01/2020 | 27 December 2021 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A05037 | 33398776 | Hepatol Int | Elobixibat, an ileal bile acid transporter inhibitor, ameliorates non-alcoholic steatohepatitis in mice. | Details |
| A06377 | 32907904 | BMJ Open | Rationale and design of a randomised, double-blind, placebo-controlled, parallel-group, investigator-initiated phase 2a study to investigate the efficacy and safety of elobixibat in combination with cholestyramine for non-alcoholic fatty liver disease. | Details |